Singh O N, Burgess J
Department of Pharmaceutics, College of Pharmacy, University of Illinois, Chicago 60612.
J Pharm Pharmacol. 1989 Oct;41(10):670-3. doi: 10.1111/j.2042-7158.1989.tb06338.x.
Complex coacervation of albumin and alginic acid has been investigated to characterize this process, and to prepare a microencapsulation system suitable for the encapsulation of live cells, protein and polypeptide drugs. The optimum conditions of pH, ionic strength and total polyion concentration were in accordance with predictions based on the method of Burgess & Carless (1984). Albumin/alginic acid complex coacervation appears to fit the Vies-Aranyi model for complex coacervation. Coacervation was limited compared with other polypeptide/polysaccharide systems such as gelatin and acacia, with albumin/alginic acid complex precipitates rather than complex coacervates forming under certain conditions. In particular coacervation was limited to concentrations below 0.5% w/v. At concentrations between 0.35 and 0.5% w/v both complex coacervation and precipitation occurred, and at concentrations above 0.5% w/v only precipitation was detected. The albumin/alginic acid complex coacervate is very viscous and this together with the limited conditions governing the occurrence of coacervation makes this system unsuitable for the preparation of microcapsules.
已对白蛋白与海藻酸的复合凝聚进行了研究,以表征此过程,并制备适用于封装活细胞、蛋白质和多肽药物的微囊化系统。pH值、离子强度和总聚离子浓度的最佳条件与基于Burgess和Carless(1984年)方法的预测一致。白蛋白/海藻酸复合凝聚似乎符合复合凝聚的Vies-Aranyi模型。与其他多肽/多糖系统(如明胶和阿拉伯胶)相比,凝聚受到限制,在某些条件下,白蛋白/海藻酸复合沉淀而非复合凝聚层形成。特别是凝聚限于浓度低于0.5%w/v。在浓度介于0.35%和0.5%w/v之间时,复合凝聚和沉淀均会发生,而在浓度高于0.5%w/v时,仅检测到沉淀。白蛋白/海藻酸复合凝聚层非常粘稠,再加上控制凝聚发生的有限条件,使得该系统不适用于制备微胶囊。